Maruo K, Ueyama Y, Inaba M, Emura R, Ohnishi Y, Nakamura O, Sato O, Nomura T
Central Institute for Experimental Animals, Kawasaki, Japan.
Anticancer Res. 1990 Jan-Feb;10(1):209-12.
Responsiveness of seven human glioma xenografts to seven antitumor agents was investigated by an sc-iv system and the efficacies of these agents against human glioma were evaluated in terms of response rate. When their maximum tolerated doses were used, experimental response rates of nimustine (ACNU), vincristine (VCR), adriamycin (ADR) and vinblastine (VLB) were as high as 86-100%, while that of mitomycin (MMC) was 57%, and those of 5-fluorouracil (5-FU) and methotrexate (MTX) were 0%. On the other hand, when the doses pharmacokinetically equivalent to their clinical doses were employed, the response rate of ADR was the highest, followed by VCR and ACNU in this order. These results suggest that gliomas are significantly responsive to various antitumor agents in this sc-iv system.
通过皮下-静脉注射系统研究了七种人胶质瘤异种移植瘤对七种抗肿瘤药物的反应性,并根据反应率评估了这些药物对人胶质瘤的疗效。当使用它们的最大耐受剂量时,尼莫司汀(ACNU)、长春新碱(VCR)、阿霉素(ADR)和长春碱(VLB)的实验反应率高达86%-100%,而丝裂霉素(MMC)为57%,5-氟尿嘧啶(5-FU)和甲氨蝶呤(MTX)为0%。另一方面,当采用药代动力学上等同于其临床剂量的剂量时,ADR的反应率最高,其次依次为VCR和ACNU。这些结果表明,在这个皮下-静脉注射系统中,胶质瘤对各种抗肿瘤药物有显著反应。